Novo Nordisk A/S (WSE:NVO)
Poland · Delayed Price · Currency is PLN | Market Cap | 703.78B -12.1% |
| Revenue (ttm) | 189.42B +5.6% |
| Net Income | 66.95B +4.8% |
| EPS | 15.48 +5.0% |
| Shares Out | n/a |
| PE Ratio | 10.41 |
| Forward PE | 12.12 |
| Dividend | 6.71 (4.17%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 395 |
| Open | 160.00 |
| Previous Close | 161.10 |
| Day's Range | 158.00 - 161.64 |
| 52-Week Range | 129.26 - 230.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk Quarterly report: Q3 2026
Novo Nordisk has published its Q3 2026 quarterly earnings report on November 4, 2026.
Novo Nordisk Slides: Q3 2026
Novo Nordisk has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
2 Reasons for Hope From Novo Nordisk Earnings
The Danish drugmaker has had a dismal year, but its third-quarter earnings on Wednesday finally gave the market a reason to feel hopeful.
Beleaguered Novo offers relief to investors, thanks to Wegovy pill
Novo Nordisk stock jumped higher on Wednesday as the Danish drugmaker lifted its guidance on strong uptake of its weight-loss drug pill that was launched this year.
Novo Reports Q3 Beat, Raises 2026 Sales Forecast on Obesity Demand; NVO Stock Jumps 5%
Novo shares ($NVO) climbed more than 5% to about $42 in Wednesday’s pre-market session after the Danish pharma giant reported third-quarter 2026 earnings that beat expectations on sales and profits.
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
The Danish drugmaker raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside of the U.S.
Novo Nordisk's CFO Karsten Munk Knudsen to leave company
Novo Nordisk's CFO Karsten Munk Knudsen to leave company
Novo raises full-year outlook as Wegovy sales impress
Novo raises full-year outlook as Wegovy sales impress
Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
Australia’s first GLP-1 weight loss pill has been approved. How much will it cost and where it will it be available?
Wegovy tablets will be going on sale soon as daily dose after TGA approval, but with restrictions and still plenty of unknowns Australia’s first GLP-1 pill for weight loss has been approved for sale, ...
Novo Nordisk A/S Repurchases B Shares Under DKK 15 Billion Programme
Novo Nordisk A/S has announced recent transactions under its share repurchase programme initiated on 6 May 2026, which operates in accordance with Safe Harbour Rules. This programme is part of an over...
3 Dirt Cheap Dividend Stocks to Buy in November 2026
AT&T, Novo Nordisk, and Vici Properties have struggled this year but remain high-quality investments. Their valuations are incredibly low, giving investors the potential to benefit from high dividends...
Novo Nordisk warns on Irish access to obesity drug after US pricing deal
Danish pharmaceutical giant, which is awaiting a HSE decision on Wegovy cover, met with the public spending minister in March
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?
Novo Nordisk is shifting its business model, with 2026 likely to represent an inflection point.
Novo Has Big Plans for 2030. Should You Buy the Stock Now?
Novo plans to expand its lineup and pipeline by 2030, while serving far more patients. The company seems well positioned to accomplish many of its goals.
Lilly’s retatrutide outshines Ozempic on weight loss, blood sugar control in trial
Eli Lilly said on Wednesday its experimental next-generation obesity drug, retatrutide, outperformed Novo Nordisk’s Ozempic on blood sugar control and delivered more than double the weight loss in a d...
Novo Stock (NVO) Falls After Another Head-to-Head Obesity Trial Loss to Eli Lilly
Shares of Danish pharma giant Novo ($NVO) edged lower to around $38 on Wednesday afternoon. This came after rival drugmaker Eli Lilly ($LLY) announced results of a head-to-head trial in…
Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trial
Eli Lilly's experimental next-generation drug retatrutide outperformed a lower-dose version of Novo Nordisk's Ozempic on blood sugar control and showed more than double weight loss in a study of adult...
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Amgen's 9.9% revenue growth outpaces Novo Nordisk, but a 33.1% net margin and lower valuation multiples tell a different profitability story.
NVO Stock Is Trading Near Its 52-Week Low. Here’s Why That Number Tells Only Part of the Story.
Novo Nordisk was the most talked-about pharmaceutical company in the world not too long ago. Ozempic had evolved from a diabetes drug into a cultural icon. Wegovy was being discussed at dinner… The po...
US judge won't block Eli Lilly ads for weight-loss drugs, rules against Novo Nordisk
A US judge on Monday rejected Novo Nordisk's request to block Eli Lilly from continuing weight-loss drug advertisements that the Danish drugmaker considered false and misleading.
Novo Nordisk A/S Reports Share Repurchase Transactions Under DKK 15 billion Programme
Novo Nordisk A/S has announced transactions under its share repurchase programme. On 6 May 2026, the company initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/20...
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
The S&P 500 remains in a confirmed uptrend, yet a big slice of the market isn't along for the ride. Money keeps crowding into the same mega-cap leaders, and plenty of solid companies sit below their 5...
FDA approves Novo Nordisk’s Awiqli for type 2 diabetes in kids 10 and older
The U.S. Food and Drug Administration has approved Awiqli injection, a long-acting insulin analog, as an adjunct to diet and exercise to improve glycemic control in pediatric patients aged 10…
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
The combined China-India-Brazil market for weight-loss drugs could grow to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan estimated, as improving affordability and broader access drive...